Swiss National Bank Athenex, Inc. Transaction History

Swiss National Bank

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 08, 2022	SELL	$1.36 - $2.94 $182,104 - $393,666	-133,900 Closed	0 $0
Q2 2021 Aug 06, 2021	BUY	$3.71 - $5.13 $21,889 - $30,267	5,900 Added 4.61%	133,900 $619,000
Q1 2021 May 07, 2021	BUY	$4.08 - $14.75 $13,464 - $48,675	3,300 Added 2.65%	128,000 $550,000
Q3 2020 Nov 09, 2020	BUY	$10.26 - $14.55 $304,722 - $432,135	29,700 Added 31.26%	124,700 $1.51 Million
Q2 2020 Aug 05, 2020	BUY	$7.11 - $13.76 $34,128 - $66,048	4,800 Added 5.32%	95,000 $1.31 Million
Q1 2020 May 08, 2020	BUY	$5.71 - $15.85 $8,565 - $23,775	1,500 Added 1.69%	90,200 $698,000
Q4 2019 Feb 06, 2020	BUY	$9.6 - $17.75 $26,880 - $49,700	2,800 Added 3.26%	88,700 $1.35 Million
Q2 2019 Aug 02, 2019	BUY	$9.44 - $19.8 $235,056 - $493,020	24,900 Added 40.82%	85,900 $1.7 Million
Q1 2019 May 10, 2019	BUY	$11.11 - $13.49 $25,553 - $31,027	2,300 Added 3.92%	61,000 $747,000
Q4 2018 Feb 13, 2019	BUY	$10.24 - $15.49 $35,840 - $54,215	3,500 Added 6.34%	58,700 $745,000
Q2 2018 Aug 09, 2018	BUY	$15.88 - $19.5 $876,576 - $1.08 Million	55,200 New	55,200 $1.03 Million

1.46M

Ticker ATNX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 156,790,000
Market Cap $1.57M
Description
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar,...

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

Stay updated on Swiss National Bank with notifications on news.